Biotech Values

[DewDiligence]

OXGN +7%/AH on phase-1b data for CA4P in ovarian cancer:

http://finance.yahoo.com/news/oxigene-announces-positive-initial-data-211500084.html

OXiGENE, Inc…today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient (pazopanib) in patients with advanced recurrent ovarian cancer.

"The initial results we've seen to date from the Phase 1b portion of PAZOFOS are encouraging and we expect to move into the phase 2 portion of the study in early 2016," said Professor Gordon Rustin, Director of Medical Oncology, Mount Vernon Cancer Centre and a chief investigator for the trial. "